7

New mutant collection examines six thousand genes. Next big thing in drug discovery?

jerry submitted, created time 4 months 5 days (stke.sciencemag.org)

A major challenge in drug discovery is to identify the cellular targets responsible for the pharmacological activity of drug candidates. In the yeast Saccharomyces cerevisiae, a heterozygous diploid mutant collection of approximately six thousand strains, in each of which one copy of a single gene is deleted, is commercially available. With this collection, it is possible to evaluate the role of each gene product in the response of cells to a drug. Drug-induced haploinsufficiency refers to the situation where a heterozygous diploid mutant is more sensitive to a drug than is the wild-type strain. Drug-induced haploinsufficiency screening has the potential to reveal pharmacological targets of drugs and those that contribute to undesired side effects, as well as gene products involved in drug transport, metabolism, or resistance...

 

Comments Who Rated and Blogged this Blog this Email this  
Who Rated This?
Who Blogged This?
    Nobody has blogged this article.
    Click here to blog it.
About Us
DiscoveR8 is a user-driven website dedicated to the dissemination and intelligent discussion of life science news, discoveries, hypotheses, and procedures. Our users are our sources, editors, and peer reviewers.
More...
Report Abuse
abuse@discover8.com
Top Investigators
More...
One-Step IP-Western Kit (Mouse)
Kit : One-Step IP-Western Kit (Mouse)
www.genscript.com
Mouse Anti HIV-1 gp41 (monoclonal)
This antibody is rabbit serum against the E. coli derived re ...
www.genscript.com
Myelin Basic Protein (MBP) (synthetic)
The synthetic peptide Myelin Basic Protein (QKRPSQRSKYL) can ...
www.genscript.com
Rabbit Anti BAD (Phospho-Ser155) (polyclonal)
antibody : Rabbit Anti BAD (Phospho-Ser155) (polyclonal) ...
www.genscript.com